A Phase 2 interventional study of AVI-4658 (Eteplirsen) in Duchenne Muscular Dystrophy (DMD), sponsored by Sarepta Therapeutics, Inc.. Completed at 11 sites in United States. Open to male participants aged 7 Years to 13 Years. Per ClinicalTrials.gov, last updated 2020-03-30.
Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 7 in phase 2, and was the 4th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →
eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 7 Years to 13 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 2
First in 2007; this study’s year is marked. 1 started in 2012.
This study's enrollment of 12 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 15 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc.: 5 open now, 6 under way, 2 of them phase 3. Of 21 finished, 15 (71%) have results posted.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 20th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2012, is one of 7 in phase 2, and was the 3rd registered.
Sarepta Therapeutics, Inc.’s Muscular Dystrophy, Duchenne studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, from their registry updates:
Among Sarepta Therapeutics, Inc.’s 27 in Muscular Dystrophy, Duchenne:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the ongoing efficacy, safety, and tolerability of an additional 212 weeks of treatment with eteplirsen injection in Duchenne muscular dystrophy (DMD) subjects who have successfully completed the 28 week eteplirsen study: Study 4658-us-201. This study will also evaluate the correlation between biomarkers for DMD and the clinical status of participating DMD subjects.
This is an open label, multiple dose extension study to assess the ongoing efficacy, safety, and tolerability of weekly intravenous (IV) infusions of eteplirsen in DMD subjects who have successfully completed Study 4658-us 201.
Subjects will have the opportunity to enroll in this study during the last visit of Study 4658-us-201 (Week 28). Eligible subjects will receive once weekly IV infusions of eteplirsen (50 or 30 mg/kg) for an additional 212 weeks. Subjects will receive the same dose of eteplirsen they received in Study 4658-us-201. Subjects will thereafter continue to receive once weekly IV infusions of eteplirsen for up to an additional 72 week period (through week 284). If commercial eteplirsen becomes available during this additional 72 week period, participation in the study will be discontinued as subjects transition to commercial eteplirsen.
Safety, efficacy, pharmacokinetic (PK), and biomarker assessments will be performed at scheduled visits; adverse events (AEs) and concomitant medications and therapies will be continuously monitored.
If review of data from this open label study suggests that continued treatment with eteplirsen is warranted, this study may be extended by protocol amendment or subjects who successfully complete this study may have the opportunity to participate in a separate follow on, open label eteplirsen study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A subject must meet all of the following criteria to be eligible for this study.
Exclusion Criteria:
A subject who meets any of the following criteria will be excluded from this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multiple-Dose Extension Study
Drug: AVI-4658 (Eteplirsen)
Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
Also known as: EXONDYS 51
Change From Baseline in the 6 Minute Walk Test (6MWT) at Week 240
This study used a modified version of the 6MWT test procedure described in American Thoracic Society (ATS) 2002 guidelines, specifically adapted for patients with Duchenne muscular dystrophy. The participant was asked to walk a set course of 25 meters for 6 minutes (timed) and the distance walked in meters was recorded. Increases from baseline in 6MWT distance are indicative of improvement and decreases from baseline indicate worsening. Baseline here corresponds to the baseline in the parent study (4658-us-201, NCT01396239).
Time frame: Parent Baseline and Week 240
Change From Baseline in the Percentage of Dystrophin Positive Fibers (PDPF) at Week 48
Dystrophin expression as assessed by percent dystrophin positive fibers was measured by immunohistochemistry (IHC) technique using primary anti-dystrophin antibody. Percent change from baseline is the arithmetic difference of the treatment time point minus baseline divided by baseline calculated for individual subjects. Baseline here corresponds to the baseline in the parent study (4658-us-201, NCT01396239).
Time frame: Parent Baseline and Week 48
The study was conducted at 12 centers in the United States. Overall, 12 participants who completed parent study 4658-us-201 (NCT01396239) were enrolled between July 2011 and February 2012 in this extension study (4658-us-202; NCT01540409). A 4-week open label period (Week 24-28) was observed between the parent and extension study.
| Milestone | Eteplirsen 30 mg/kg | Eteplirsen 50 mg/kg |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
This study used a modified version of the 6MWT test procedure described in American Thoracic Society (ATS) 2002 guidelines, specifically adapted for patients with Duchenne muscular dystrophy. The participant was asked to walk a set course of 25 meters for 6 minutes (timed) and the distance walked in meters was recorded. Increases from baseline in 6MWT distance are indicative of improvement and decreases from baseline indicate worsening. Baseline here corresponds to the baseline in the parent study (4658-us-201, NCT01396239).
| Meters | Eteplirsen 30 mg/kg | Eteplirsen 50 mg/kg |
|---|---|---|
| Change From Baseline in the 6 Minute Walk Test (6MWT) at Week 240 | -199.0 ± 113.25 | -258.0 ± 175.65 |
Dystrophin expression as assessed by percent dystrophin positive fibers was measured by immunohistochemistry (IHC) technique using primary anti-dystrophin antibody. Percent change from baseline is the arithmetic difference of the treatment time point minus baseline divided by baseline calculated for individual subjects. Baseline here corresponds to the baseline in the parent study (4658-us-201, NCT01396239).
| Percentage of Dystrophin Positive Fibers | Placebo to Eteplirsen | Eteplirsen 30 mg/kg | Eteplirsen 50 mg/kg |
|---|---|---|---|
| Change From Baseline in the Percentage of Dystrophin Positive Fibers (PDPF) at Week 48 | 37.70 ± 12.602 | 51.69 ± 7.089 | 42.93 ± 13.433 |
Collected over Parent Baseline up to 240 weeks (cumulative Study 4658-us-201 + 4658-us-202). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eteplirsen 30 mg/kg | 0/6 (0%) | 4/6 (66.7%) | 6/6 (100%) |
| Eteplirsen 50 mg/kg | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | Eteplirsen 30 mg/kg | Eteplirsen 50 mg/kg |
|---|---|---|
| Femur FractureInjury, poisoning and procedural complications | 3/6 | 1/6 |
| ScoliosisMusculoskeletal and connective tissue disorders | 2/6 | 0/6 |
| Tibia FractureInjury, poisoning and procedural complications | 0/6 | 1/6 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/6 | 0/6 |
| Event | Eteplirsen 30 mg/kg | Eteplirsen 50 mg/kg |
|---|---|---|
| Procedural painInjury, poisoning and procedural complications | 5/6 | 6/6 |
| Back painMusculoskeletal and connective tissue disorders | 6/6 | 3/6 |
| HeadacheNervous system disorders | 4/6 | 5/6 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 5/6 | 2/6 |
| VomitingGastrointestinal disorders | 5/6 | 4/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/6 | 4/6 |
| NasopharyngitisInfections and infestations | 4/6 | 5/6 |
| ContusionInjury, poisoning and procedural complications | 4/6 | 4/6 |
| Activated partial thromboplastin time prolongedInvestigations | 0/6 | 4/6 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 4/6 | 4/6 |
The safety population included all randomized participants who received any amount of study drug.
| Age, Continuous(years) | Eteplirsen 30 mg/kg | Eteplirsen 50 mg/kg | Total |
|---|---|---|---|
| Mean | 9.2 ± 0.75 | 8.8 ± 1.47 | 9.0 ± 1.13 |
| Sex: Female, Male(Participants) | Eteplirsen 30 mg/kg | Eteplirsen 50 mg/kg | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 6 | 6 | 12 |
| Region of Enrollment(Participants) | Eteplirsen 30 mg/kg | Eteplirsen 50 mg/kg | Total |
|---|---|---|---|
| United States | 6 | 6 | 12 |
Ran from Feb 2012 to primary completion in Apr 2016, 49 months.
Results were first posted in Jul 2019, 3 years 2 months after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 49 months is above that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eteplirsen
Muscular Dystrophy, Duchenne →